sulthiame has been researched along with Aura in 42 studies
sulthiame: was heading 1964-94 (see under THIAZINES 1964-90); use THIAZINES to search SULTHIAME 1966-94
| Excerpt | Relevance | Reference |
|---|---|---|
| "To show non-inferiority of levetiracetam to sulthiame with respect to efficacy, tolerability and safety in benign epilepsy with centrotemporal spikes in a prospective, double-blinded randomized controlled trial." | 9.17 | Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). ( Bast, T; Bonfert, M; Borggraefe, I; Heinen, F; Maßmann, K; May, TW; Neubauer, BA; Noachtar, S; Schotten, KJ; Tuxhorn, I, 2013) |
| " Small sample sizes, poor methodological quality, and lack of data on important outcome measures precluded any meaningful conclusions regarding the efficacy and tolerability of sulthiame as monotherapy in epilepsy." | 9.12 | Sulthiame monotherapy for epilepsy. ( Marson, AG; Milburn-McNulty, P; Panebianco, M, 2021) |
| "This prospective uncontrolled open study explored the efficacy and long-term tolerability of sulthiame (STM) in 52 patients with refractory epilepsy and learning disability." | 9.10 | Sulthiame in adults with refractory epilepsy and learning disability: an open trial. ( Koepp, MJ; Patsalos, PN; Sander, JW, 2002) |
| "To assess the efficacy and tolerability of sulthiame as add-on therapy for people with epilepsy of any aetiology compared with placebo or another antiepileptic drug." | 9.01 | Sulthiame add-on therapy for epilepsy. ( Bresnahan, R; Marson, AG; Martin-McGill, KJ; Milburn-McNulty, P; Powell, G; Sills, GJ, 2019) |
| "Randomised controlled add-on trials of sulthiame in people of any age with epilepsy of any aetiology." | 8.91 | Sulthiame add-on therapy for epilepsy. ( Marson, AG; Milburn-McNulty, P; Powell, G; Sills, GJ, 2015) |
| "Small sample size, poor methodological quality and lack of data on important outcome measures prevent any meaningful conclusions regarding the efficacy and safety of sulthiame as monotherapy in epilepsy." | 8.90 | Sulthiame monotherapy for epilepsy. ( Marson, AG; Milburn-McNulty, P; Powell, G; Sills, GJ, 2014) |
| "Randomised placebo-controlled add-on trials of sulthiame in people of any age with epilepsy of any aetiology." | 8.89 | Sulthiame add-on therapy for epilepsy. ( Marson, AG; Milburn-McNulty, P; Powell, G; Sills, GJ, 2013) |
| "The charts of 125 consecutive epilepsy patients treated with sulthiame as monotherapy or add-on therapy were reviewed." | 7.72 | Sulthiame in childhood epilepsy. ( Barash, I; Ben-Zeev, B; Brand, N; Lerman, P; Lerman-Sagie, T; Watemberg, N, 2004) |
| "Sulthiame is effectively used in the treatment of benign and symptomatic focal epilepsy in children." | 7.69 | Sulthiame-associated mild compensated metabolic acidosis. ( Darius, J; Fritzsch, C; Gedschold, J; Meyer, FP; Tröger, U, 1996) |
| "9%) seizure frequency was reduced by more than 50% (mean FBM dosage 3211 mg), and 13 patients (31." | 5.34 | [Treatment of epilepsy with third-line antiepileptic drugs: felbamate, tiagabine, and sulthiame]. ( Bauer, J; Chahem, J, 2007) |
| "To show non-inferiority of levetiracetam to sulthiame with respect to efficacy, tolerability and safety in benign epilepsy with centrotemporal spikes in a prospective, double-blinded randomized controlled trial." | 5.17 | Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). ( Bast, T; Bonfert, M; Borggraefe, I; Heinen, F; Maßmann, K; May, TW; Neubauer, BA; Noachtar, S; Schotten, KJ; Tuxhorn, I, 2013) |
| " Small sample sizes, poor methodological quality, and lack of data on important outcome measures precluded any meaningful conclusions regarding the efficacy and tolerability of sulthiame as monotherapy in epilepsy." | 5.12 | Sulthiame monotherapy for epilepsy. ( Marson, AG; Milburn-McNulty, P; Panebianco, M, 2021) |
| "This prospective uncontrolled open study explored the efficacy and long-term tolerability of sulthiame (STM) in 52 patients with refractory epilepsy and learning disability." | 5.10 | Sulthiame in adults with refractory epilepsy and learning disability: an open trial. ( Koepp, MJ; Patsalos, PN; Sander, JW, 2002) |
| "To assess the efficacy and tolerability of sulthiame as add-on therapy for people with epilepsy of any aetiology compared with placebo or another antiepileptic drug." | 5.01 | Sulthiame add-on therapy for epilepsy. ( Bresnahan, R; Marson, AG; Martin-McGill, KJ; Milburn-McNulty, P; Powell, G; Sills, GJ, 2019) |
| "Randomised controlled add-on trials of sulthiame in people of any age with epilepsy of any aetiology." | 4.91 | Sulthiame add-on therapy for epilepsy. ( Marson, AG; Milburn-McNulty, P; Powell, G; Sills, GJ, 2015) |
| "Small sample size, poor methodological quality and lack of data on important outcome measures prevent any meaningful conclusions regarding the efficacy and safety of sulthiame as monotherapy in epilepsy." | 4.90 | Sulthiame monotherapy for epilepsy. ( Marson, AG; Milburn-McNulty, P; Powell, G; Sills, GJ, 2014) |
| "Randomised placebo-controlled add-on trials of sulthiame in people of any age with epilepsy of any aetiology." | 4.89 | Sulthiame add-on therapy for epilepsy. ( Marson, AG; Milburn-McNulty, P; Powell, G; Sills, GJ, 2013) |
| "The introduction of these new antiepileptic drugs, from felbamate to levetiracetam, raised hope of control of epilepsy with fewer adverse effects and improved quality of life." | 4.81 | New antiepileptic drug therapies. ( Bergin, AM; Connolly, M, 2002) |
| "Sulthiame is an old antiepileptic drug primarily used in a few European countries for the treatment of benign epilepsy of childhood with central temporal spikes." | 3.77 | Sulthiame in refractory paediatric epilepsies: an experience of an 'old' antiepileptic drug in a tertiary paediatric neurology unit. ( Appleton, R; Eaton, V; Hawcutt, D; Kneen, R; Kumar, R; Stockton, F; Swiderska, N, 2011) |
| "The charts of 125 consecutive epilepsy patients treated with sulthiame as monotherapy or add-on therapy were reviewed." | 3.72 | Sulthiame in childhood epilepsy. ( Barash, I; Ben-Zeev, B; Brand, N; Lerman, P; Lerman-Sagie, T; Watemberg, N, 2004) |
| "Sulthiame is a carbonic anhydrase (CA) inhibitor with an anticonvulsant effect in the treatment of benign and symptomatic focal epilepsy in children." | 3.71 | Carbonic anhydrase inhibitor sulthiame reduces intracellular pH and epileptiform activity of hippocampal CA3 neurons. ( Bingmann, D; Bonnet, U; Hufnagel, A; Leniger, T; Widman, G; Wiemann, M, 2002) |
| "Sulthiame is effectively used in the treatment of benign and symptomatic focal epilepsy in children." | 3.69 | Sulthiame-associated mild compensated metabolic acidosis. ( Darius, J; Fritzsch, C; Gedschold, J; Meyer, FP; Tröger, U, 1996) |
| "9%) seizure frequency was reduced by more than 50% (mean FBM dosage 3211 mg), and 13 patients (31." | 1.34 | [Treatment of epilepsy with third-line antiepileptic drugs: felbamate, tiagabine, and sulthiame]. ( Bauer, J; Chahem, J, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (52.38) | 18.7374 |
| 1990's | 1 (2.38) | 18.2507 |
| 2000's | 7 (16.67) | 29.6817 |
| 2010's | 9 (21.43) | 24.3611 |
| 2020's | 3 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Milburn-McNulty, P | 5 |
| Panebianco, M | 1 |
| Marson, AG | 5 |
| Bresnahan, R | 1 |
| Martin-McGill, KJ | 1 |
| Powell, G | 4 |
| Sills, GJ | 4 |
| Madej, K | 1 |
| Paprotny, Ł | 1 |
| Wianowska, D | 1 |
| Kasprzyk, J | 1 |
| Herman, M | 1 |
| Piekoszewski, W | 1 |
| Liguori, S | 1 |
| Borggraefe, I | 1 |
| Bonfert, M | 1 |
| Bast, T | 1 |
| Neubauer, BA | 1 |
| Schotten, KJ | 1 |
| Maßmann, K | 1 |
| Noachtar, S | 1 |
| Tuxhorn, I | 1 |
| May, TW | 1 |
| Heinen, F | 1 |
| Yamamoto, Y | 1 |
| Takahashi, Y | 1 |
| Imai, K | 1 |
| Mogami, Y | 1 |
| Matsuda, K | 1 |
| Nakai, M | 1 |
| Kagawa, Y | 1 |
| Inoue, Y | 1 |
| Tan, HJ | 1 |
| Singh, J | 1 |
| Gupta, R | 1 |
| de Goede, C | 1 |
| Rauchenzauner, M | 1 |
| Griesmacher, A | 1 |
| Tatarczyk, T | 1 |
| Haberlandt, E | 1 |
| Strasak, A | 1 |
| Zimmerhackl, LB | 1 |
| Falkensammer, G | 1 |
| Luef, G | 1 |
| Högler, W | 1 |
| Swiderska, N | 1 |
| Hawcutt, D | 1 |
| Eaton, V | 1 |
| Stockton, F | 1 |
| Kumar, R | 1 |
| Kneen, R | 1 |
| Appleton, R | 1 |
| Koepp, MJ | 1 |
| Patsalos, PN | 1 |
| Sander, JW | 1 |
| Bergin, AM | 1 |
| Connolly, M | 1 |
| ENGELMEIER, MP | 1 |
| FLUEGEL, F | 1 |
| BENTE, D | 1 |
| ITIL, T | 1 |
| RAFFAUF, HJ | 1 |
| HAJNSEK, F | 1 |
| BOHACEK, N | 1 |
| OVERVAD, E | 1 |
| HARAN, T | 2 |
| INGRAM, TT | 1 |
| RATCLIFFE, SG | 1 |
| TAEN, S | 1 |
| GOTO, Y | 1 |
| ARAI, S | 1 |
| TOKUDA, Y | 1 |
| ODAWARA, K | 1 |
| HIRAI, M | 1 |
| BRAY, CA | 1 |
| BOWER, BD | 1 |
| SUTHERLAND, JM | 1 |
| BOWMAN, DA | 1 |
| GARLAND, H | 1 |
| SUMNER, D | 1 |
| GRIFFITHS, AW | 1 |
| SYLVESTER, PE | 1 |
| DOOSE, H | 1 |
| KLUGE, D | 1 |
| EHMSEN, U | 1 |
| GORDON, N | 2 |
| FENTON, G | 1 |
| SERAFETINIDES, EA | 1 |
| POND, DA | 1 |
| MELIN, KA | 1 |
| GAYLOR, JB | 1 |
| SMYTH, VO | 1 |
| SONNENREICH, C | 1 |
| RABE, F | 1 |
| PENIN, H | 1 |
| MATTHES, A | 1 |
| Go, T | 1 |
| Ben-Zeev, B | 1 |
| Watemberg, N | 1 |
| Lerman, P | 1 |
| Barash, I | 1 |
| Brand, N | 1 |
| Lerman-Sagie, T | 1 |
| Huppke, P | 1 |
| Kallenberg, K | 1 |
| Gärtner, J | 1 |
| Chahem, J | 1 |
| Bauer, J | 1 |
| Tröger, U | 1 |
| Fritzsch, C | 1 |
| Darius, J | 1 |
| Gedschold, J | 1 |
| Meyer, FP | 1 |
| Leniger, T | 1 |
| Wiemann, M | 1 |
| Bingmann, D | 1 |
| Widman, G | 1 |
| Hufnagel, A | 1 |
| Bonnet, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| HEAD-TO-HEAD Evaluation of the Antiepileptic Drugs Levetiracetam (LEV) vs. Sulthiame (STM) in a German Multi-Centre, Doubleblind Controlled Trial in Children With Benign Epilepsy With Centro-Temporal Spikes[NCT00471744] | Phase 3 | 44 participants (Actual) | Interventional | 2006-06-30 | Terminated (stopped due to low patient number after 2 years recruiting) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for sulthiame and Aura
| Article | Year |
|---|---|
Sulthiame monotherapy for epilepsy.
Topics: Anticonvulsants; Epilepsy; Humans; Quality of Life; Randomized Controlled Trials as Topic; Thiazines | 2021 |
Sulthiame add-on therapy for epilepsy.
Topics: Anticonvulsants; Drug Therapy, Combination; Epilepsy; Female; Humans; Infant; Male; Quality of Life; | 2019 |
Sulthiame add-on therapy for epilepsy.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Infant; Male; Randomized Controlled Trials as Topic; Spas | 2013 |
Sulthiame monotherapy for epilepsy.
Topics: Adult; Anticonvulsants; Child; Child, Preschool; Early Termination of Clinical Trials; Epilepsy; Epi | 2014 |
Comparison of antiepileptic drugs, no treatment, or placebo for children with benign epilepsy with centro temporal spikes.
Topics: Anticonvulsants; Benzodiazepines; Carbamazepine; Child; Clobazam; Epilepsy; Fructose; Humans; Induct | 2014 |
Sulthiame add-on therapy for epilepsy.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Infant; Male; Pyridoxine; Randomized Controlled Trials as | 2015 |
New antiepileptic drug therapies.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Dioxolanes; Ep | 2002 |
ADVANCES IN NEUROLOGY.
Topics: Drug Therapy; Epilepsy; Headache; Methysergide; Migraine Disorders; Multiple Sclerosis; Nervous Syst | 1964 |
2 trials available for sulthiame and Aura
| Article | Year |
|---|---|
Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study).
Topics: Anticonvulsants; Child; Double-Blind Method; Drug Therapy, Combination; Epilepsy; Female; Humans; Le | 2013 |
Sulthiame in adults with refractory epilepsy and learning disability: an open trial.
Topics: Adult; Epilepsy; Female; Follow-Up Studies; Humans; Learning Disabilities; Male; Middle Aged; Neutro | 2002 |
32 other studies available for sulthiame and Aura
| Article | Year |
|---|---|
A fully validated HPLC-UV method for determination of sulthiame in human serum/plasma samples.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Chromatography, High Pressure Liquid; D | 2021 |
Is sulthiame effective and tolerated as add-on therapy for infants with epilepsy? A Cochrane Review summary with commentary.
Topics: Epilepsy; Humans; Infant; Thiazines | 2021 |
Interaction between sulthiame and clobazam: sulthiame inhibits the metabolism of clobazam, possibly via an action on CYP2C19.
Topics: Adult; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam; Cytochrome P-450 CYP2C19 | 2014 |
Chronic antiepileptic monotherapy, bone metabolism, and body composition in non-institutionalized children.
Topics: Anthropometry; Anticonvulsants; Body Composition; Body Height; Body Mass Index; Body Weight; Carbama | 2010 |
Sulthiame in refractory paediatric epilepsies: an experience of an 'old' antiepileptic drug in a tertiary paediatric neurology unit.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Hospital Units; Humans; Male | 2011 |
[On the clinical evaluation of anti-epileptic medications with special reference to Ospolot].
Topics: Anticonvulsants; Epilepsy; Heterocyclic Compounds; Thiazines | 1960 |
[On the role of the butanesultam derivative Ospolot in the treatment of cerebral epilepsy].
Topics: Anticonvulsants; Epilepsy; Heterocyclic Compounds; Thiazines | 1960 |
[The treatment of cerebral epilepsy with Ospolot].
Topics: Anticonvulsants; Epilepsy; Heterocyclic Compounds; Thiazines | 1960 |
[Our experience in the therapy of some refractory forms of epilepsy with Ospolot].
Topics: Cardiovascular Agents; Epilepsy; Heterocyclic Compounds; Muscle Relaxants, Central; Thiazines | 1961 |
[Ospolot, a new preparation for the treatment of epilepsy].
Topics: Epilepsy; Heterocyclic Compounds; Thiazines | 1962 |
OSPOLOT: a preliminary communication.
Topics: Anticonvulsants; Communication; Epilepsy; Heterocyclic Compounds; Thiazines | 1962 |
Clinical trial of Ospolot in epilepsy.
Topics: Anticonvulsants; Epilepsy; Humans; Thiazines | 1963 |
[Therapeutic effect of N-(4-sulfamoylphenyl)-1,4-butanesultam (Ospolot) on epilepsy].
Topics: Anticonvulsants; Epilepsy; Thiazines | 1962 |
OSPOLOT IN EPILEPSY.
Topics: Adolescent; Anticonvulsants; Child; Epilepsy; Humans; Infant; Thiazines; Toxicology | 1963 |
SULTHIAMINE ("OSPOLOT") IN THE TREATMENT OF TEMPORAL LOBE EPILEPSY.
Topics: Adolescent; Anticonvulsants; Child; Epilepsy; Epilepsy, Temporal Lobe; Humans; Infant; Temporal Lobe | 1963 |
SULTHIAME IN TREATMENT OF EPILEPSY.
Topics: Adolescent; Anticonvulsants; Epilepsy; Pharmacology; Statistics as Topic; Sulfanilamide; Sulfanilami | 1964 |
SULTHIAME TREATMENT OF EPILEPSY.
Topics: Anticonvulsants; Dysmenorrhea; Epilepsy; Female; Humans; Thiazines; Toxicology | 1964 |
OSPOLOT--A CLINICAL TRIAL OF A NEW ANTICONVULSANT.
Topics: Anticonvulsants; Electroencephalography; Epilepsy; Humans; Intellectual Disability; Pathology; Pharm | 1964 |
[EXPERIENCES WITH OSPOLOT IN THE TREATMENT OF INFANTILE EPILEPSY].
Topics: Anticonvulsants; Child; Epilepsy; Epilepsy, Absence; Epilepsy, Temporal Lobe; Epilepsy, Tonic-Clonic | 1964 |
SULTHIAME (OSPOLOT) IN THE TREATMENT OF EPILEPSY.
Topics: Anticonvulsants; Child; Child Behavior Disorders; Epilepsy; Epilepsy, Temporal Lobe; Epilepsy, Tonic | 1964 |
THE USE OF OSPOLOT IN THE TREATMENT OF EPILEPSY.
Topics: Anticonvulsants; Biomedical Research; Child; Drug Therapy; Epilepsy; Epilepsy, Absence; Epilepsy, Te | 1964 |
THE EFFECT OF SULTHIAME, A NEW ANTICONVULSANT DRUG IN THE TREATMENT OF TEMPORAL LOBE EPILEPSY.
Topics: Adolescent; Anticonvulsants; Drug Therapy; Dyspnea; Epilepsy; Epilepsy, Temporal Lobe; Humans; Paran | 1964 |
[OSPOLOT, A NEW ANTICONVULSANT. REPORT SUMMING UP 2 YEARS OF CLINICAL TRIALS].
Topics: Adolescent; Anticonvulsants; Child; Epilepsy; Heterocyclic Compounds; Humans; Thiazines | 1964 |
THE USE OF OSPOLOT IN TEMPORAL LOBE EPILEPSY. A PRELIMINARY COMMUNICATION.
Topics: Anticonvulsants; Drug Therapy; Epilepsy; Epilepsy, Temporal Lobe; Heterocyclic Compounds; Humans; Te | 1964 |
[OSPOLOT IN EPILEPSY TREATMENT].
Topics: Anticonvulsants; Drug Therapy; Epilepsy; Thiazines | 1965 |
[Experiences with Ospolot in the treatment of epilepsy].
Topics: Epilepsy; Heterocyclic Compounds; Thiazines | 1962 |
Effect of antiepileptic drug monotherapy on crystalluria in children and young adults.
Topics: Adolescent; Anticonvulsants; Child; Epilepsy; Female; Humans; Isoxazoles; Male; Retrospective Studie | 2003 |
Sulthiame in childhood epilepsy.
Topics: Adolescent; Australia; Child; Child, Preschool; Dose-Response Relationship, Drug; Epilepsy; Female; | 2004 |
Perisylvian polymicrogyria in Landau-Kleffner syndrome.
Topics: Cerebral Arteries; Cerebral Cortex; Child; Electroencephalography; Epilepsy; Humans; Landau-Kleffner | 2005 |
[Treatment of epilepsy with third-line antiepileptic drugs: felbamate, tiagabine, and sulthiame].
Topics: Adult; Anticonvulsants; Epilepsy; Felbamate; Humans; Nipecotic Acids; Phenylcarbamates; Propylene Gl | 2007 |
Sulthiame-associated mild compensated metabolic acidosis.
Topics: Acidosis; Anticonvulsants; Blood Gas Analysis; Child, Preschool; Epilepsy; Humans; Male; Thiazines | 1996 |
Carbonic anhydrase inhibitor sulthiame reduces intracellular pH and epileptiform activity of hippocampal CA3 neurons.
Topics: Acetazolamide; Animals; Anticonvulsants; Benzolamide; Carbonic Anhydrase Inhibitors; Epilepsy; Guine | 2002 |